Lexeo Therapeutics, Inc. (LXEO) Common Equity (2022 - 2023)
Lexeo Therapeutics' Common Equity history spans 2 years, with the latest figure at -$162.8 million for Q3 2023.
- For Q3 2023, Common Equity fell 64.49% year-over-year to -$162.8 million; the TTM value through Sep 2023 reached -$162.8 million, down 64.49%, while the annual FY2022 figure was -$113.0 million, N/A changed from the prior year.
- Common Equity for Q3 2023 was -$162.8 million at Lexeo Therapeutics, down from -$143.6 million in the prior quarter.
- Across five years, Common Equity topped out at -$99.0 million in Q3 2022 and bottomed at -$162.8 million in Q3 2023.